Tracy L. Matlock

Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $20 billion in aggregate principal amount of senior notes by Halfmoon Parent,…

Davis Polk advised the representatives of the several underwriters in an SEC-registered offering of $400 million in aggregate principal amount of Black Hills Corporation’s 4.350%…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…

Davis Polk is advising Ankura Consulting Group, LLC on its acquisition of C3 Consulting, LLC. The transaction is expected to close by the end of the month, subject to customary closing…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant…

Davis Polk advised the joint book-running managers and the initial purchasers in a Rule 144A/Regulation S offering of $325 million principal amount of senior notes due 2026 of WMG…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of senior notes by Ingersoll-Rand Global…

Davis Polk advised the dealer managers in connection with the offers by Intel Corporation to exchange any and all of its outstanding $1.5 billion 4.80% senior notes due 2041, $925…

Davis Polk advised the sole underwriter in connection with a block trade of 10,000,000 common shares of Genpact Limited by funds affiliated with Bain Capital Investors, LLC and its co…

Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health…